Merck to present new long-term data for tulisokibart (MK-7240)

Merck announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor-like cytokine 1A, in ulcerative colitis and Crohn’s disease will be presented at the United European Gastroenterology Week 2024 Congress in Vienna, Austria. Long-term efficacy and safety data for tulisokibart from the open-label extension period of the Phase 2 ARTEMIS-UC and APOLLO-CD studies will be featured in two oral presentations. In both studies, at week 50, maintenance of treatment efficacy was generally observed in 12-week induction responders. The observed safety profile in the study extensions was consistent with previously reported data.